-DOCSTART- -X- O
Virus-like -X- _ B-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLPs -X- _ I-Intervention
) -X- _ I-Intervention
can -X- _ O
be -X- _ O
spontaneously -X- _ O
self-assembled -X- _ O
by -X- _ O
viral -X- _ O
structural -X- _ O
proteins -X- _ O
under -X- _ O
appropriate -X- _ O
conditions -X- _ O
in -X- _ O
vitro -X- _ O
while -X- _ O
excluding -X- _ O
the -X- _ O
genetic -X- _ O
material -X- _ O
and -X- _ O
potential -X- _ O
replication -X- _ O
probability. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
VLPs -X- _ B-Intervention
possess -X- _ O
several -X- _ O
features -X- _ O
including -X- _ O
can -X- _ O
be -X- _ O
rapidly -X- _ O
produced -X- _ O
in -X- _ O
large -X- _ O
quantities -X- _ O
through -X- _ O
existing -X- _ O
expression -X- _ O
systems -X- _ O
, -X- _ O
highly -X- _ O
resembling -X- _ O
native -X- _ O
viruses -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
conformation -X- _ O
and -X- _ O
appearance -X- _ O
, -X- _ O
and -X- _ O
displaying -X- _ O
repeated -X- _ O
cluster -X- _ O
of -X- _ O
epitopes. -X- _ O
Their -X- _ B-Outcome
capsids -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
modified -X- _ I-Outcome
via -X- _ I-Outcome
genetic -X- _ I-Outcome
insertion -X- _ I-Outcome
or -X- _ I-Outcome
chemical -X- _ I-Outcome
conjugation -X- _ I-Outcome
which -X- _ I-Outcome
facilitating -X- _ I-Outcome
the -X- _ I-Outcome
multivalent -X- _ I-Outcome
display -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
homologous -X- _ I-Outcome
or -X- _ I-Outcome
heterogeneous -X- _ I-Outcome
epitope -X- _ I-Outcome
antigen. -X- _ I-Outcome
Therefore -X- _ O
, -X- _ O
VLPs -X- _ B-Intervention
are -X- _ O
considered -X- _ O
as -X- _ O
a -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
candidate -X- _ O
of -X- _ O
prophylactic -X- _ O
and -X- _ O
therapeutic -X- _ O
vaccines. -X- _ O
VLPs -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
diameter -X- _ O
of -X- _ O
approximately -X- _ O
20 -X- _ O
to -X- _ O
150 -X- _ O
nm -X- _ O
, -X- _ O
also -X- _ O
have -X- _ O
the -X- _ O
characteristics -X- _ O
of -X- _ O
nanometer -X- _ O
materials -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
large -X- _ O
surface -X- _ O
area -X- _ O
, -X- _ O
surface-accessible -X- _ O
amino -X- _ O
acids -X- _ O
with -X- _ O
reactive -X- _ O
moieties -X- _ O
( -X- _ O
e.g. -X- _ O
, -X- _ O
lysine -X- _ O
and -X- _ O
glutamic -X- _ O
acid -X- _ O
residues -X- _ O
) -X- _ O
, -X- _ O
inerratic -X- _ O
spatial -X- _ O
structure -X- _ O
, -X- _ O
and -X- _ O
good -X- _ O
biocompatibility. -X- _ O
Therefore -X- _ O
, -X- _ O
assembled -X- _ B-Outcome
VLPs -X- _ I-Outcome
have -X- _ I-Outcome
great -X- _ I-Outcome
potential -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
delivery -X- _ I-Outcome
system -X- _ I-Outcome
for -X- _ I-Outcome
specifically -X- _ I-Outcome
carrying -X- _ I-Outcome
a -X- _ I-Outcome
variety -X- _ I-Outcome
of -X- _ I-Outcome
materials. -X- _ I-Outcome
This -X- _ O
review -X- _ O
summarized -X- _ O
recent -X- _ O
researches -X- _ O
on -X- _ O
VLP -X- _ O
development -X- _ O
as -X- _ O
vaccines -X- _ O
and -X- _ O
biological -X- _ O
vehicles -X- _ O
, -X- _ O
which -X- _ O
demonstrated -X- _ O
the -X- _ O
advantages -X- _ O
and -X- _ O
potential -X- _ O
of -X- _ O
VLPs -X- _ O
in -X- _ O
disease -X- _ O
control -X- _ O
and -X- _ O
prevention -X- _ O
and -X- _ O
diagnosis. -X- _ O
Then -X- _ O
, -X- _ O
the -X- _ O
prospect -X- _ O
of -X- _ O
VLP -X- _ O
biology -X- _ O
application -X- _ O
in -X- _ O
the -X- _ O
future -X- _ O
is -X- _ O
discussed -X- _ O
as -X- _ O
well -X- _ O
. -X- _ O

